Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis
First patient dosed in global study of oral α4β7 integrin inhibitor
Excerpt from the Press Release:
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that the EMERALD-2 phase 2b study of MORF-057 in ulcerative colitis (UC) has commenced with the first patient receiving MORF-057.
“MORF-057 offers the possibility of efficacy and tolerability through the proven mechanism of α4β7 inhibition, together with the ease and convenience of oral dosing for patients suffering from IBD,” commented Praveen Tipirneni, CEO of Morphic Therapeutic. “We are therefore extremely excited to begin the EMERALD-2 study of MORF-057. In addition, we are now eagerly looking forward to the results of the EMERALD-1 phase 2a study of MORF-057 that we expect in second quarter of 2023.”
About the EMERALD-2 Study
EMERALD-2 (MORF-057-202) is a global phase 2b randomized, double-blind, placebo-controlled trial of MORF-057 in patients with moderate-to-severe ulcerative colitis. The primary endpoint of EMERALD-2 is clinical remission rate as measured by the Modified Mayo Clinic Score (mMCS) at 12 weeks. EMERALD-2 will also measure several secondary and exploratory endpoints based on the mMCS as well as histologic, pharmacokinetic and pharmacodynamic measures, and safety parameters.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?